• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863).
  
• Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863).
  
• Gene deletion; HGNC; HGNC:6190; JAK1; Zygosity=Heterozygous (PubMed=28561041).
  
• Gene fusion; HGNC; HGNC:7413; MTAP + HGNC; HGNC:34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
  

PubMed=23348503; DOI=10.1126/science.1230062
Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.
TERT promoter mutations in familial and sporadic melanoma.
Science 339:959-961(2013)

PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330
Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A., Hemminki K., Schadendorf D., Kumar R.
Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.
Oncotarget 7:16490-16504(2016)

PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020
Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N., Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S., Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M., Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G., Paschen A.
Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Nat. Commun. 8:15440.1-15440.15(2017)